Efficacy and safety of edoxaban following danaparoid sodium administration for treatment of portal vein thrombosis in patients with cirrhosis

DOI Web Site
  • Yuko Nagaoki
    Department of Gastroenterology and Metabolism, Applied Life Science, Institute of Biomedical & Health Science, Hiroshima University
  • Hiroshi Aikata
    Department of Gastroenterology and Metabolism, Applied Life Science, Institute of Biomedical & Health Science, Hiroshima University Liver Research Project Center, Hiroshima University
  • Kazuaki Chayama
    Department of Gastroenterology and Metabolism, Applied Life Science, Institute of Biomedical & Health Science, Hiroshima University Liver Research Project Center, Hiroshima University Laboratory for Digestive Diseases, RIKEN Center for Integrative Medical Sciences

Bibliographic Information

Other Title
  • 肝硬変合併門脈血栓症に対するダナパロイドNa先行エドキサバンの有効性，安全性
  • 肝硬変合併門脈血栓症に対するダナパロイドNa先行エドキサバンの有効性,安全性 : warfarinとの比較
  • カンコウヘン ガッペイ モンミャク ケッセンショウ ニ タイスル ダナパロイド Na センコウ エドキサバン ノ ユウコウセイ,アンゼンセイ : warfarin ト ノ ヒカク
  • ―warfarinとの比較―

Search this article

Abstract

<p>Aim: To evaluate the efficacy and safety of edoxaban in comparison with warfarin for treatment of portal vein thrombosis (PVT) following danaparoid sodium administration in patients with cirrhosis.</p><p>Methods: 64 cirrhotic patients with PVT treated initially for 2 weeks by danaparoid sodium were enrolled retrospectively. In all patients, either edoxaban (n = 34) or warfarin (n = 30) were administrated then later. The efficacy and safety of edoxaban were compared to those of warfarin for up to 6 months. PVT volume was measured by dynamic CT at baseline and at 2 weeks, 1, 3 and 6 months.</p><p>Results: Significant differences in clinical characteristics of patients were not found between both groups. Edoxaban intakes reduced volume of PVT from 1.72 cm3 at 2 weeks to 0.44 cm3 at 6 months, and prevented exacerbation of PVT at 6 months after treatment with danaparoid sodium (p = 0.008). Warfarin intakes, however, resulted in increase of PVT volume from 1.37 cm3 at 2 weeks to 2.65 cm3 at 6 months, despite that prothrombin time international normalized ratio (INR) of 1.5 or more was maintained in 57% of patients (p = 0.005). Multivariate regression analysis identified edoxaban therapy as a single significant and independent determinant contributing PVT reduction at 6 months (p<0.001). Gastrointestinal bleeding occurred in 4 of 34 (12%) patients in the edoxaban group, while 2 of 30 (7%) in the warfarin group (p = 0.485).</p><p>Conclusion: Edoxaban intakes following danaparoid sodium administration were effective and merit consideration as one of therapeutic options for PVT in cirrhotic patients.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top